- Home
- CFLT vs LNTH Comparison
CFLT vs LNTH Comparison
Compare CFLT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CFLT | LNTH |
|---|---|---|
| Founded | 2014 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 4.4B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CFLT | LNTH |
|---|---|---|
| Price | $30.12 | $67.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 6 |
| Target Price | $29.93 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 20.2M | 1.1M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | $1,113,149,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $22.76 | $0.01 |
| Revenue Next Year | $16.57 | $0.52 |
| P/E Ratio | ★ N/A | $28.11 |
| Revenue Growth | ★ 21.57 | 1.95 |
| 52 Week Low | $15.64 | $47.25 |
| 52 Week High | $37.90 | $111.29 |
Technical Indicators
Market Signals| Indicator | CFLT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 75.42 | 64.91 |
| Support Level | $29.95 | $66.36 |
| Resistance Level | $30.33 | $67.45 |
| Average True Range (ATR) | 0.12 | 1.65 |
| MACD | -0.18 | -0.15 |
| Stochastic Oscillator | 44.16 | 64.97 |
Price Performance
Historical ComparisonAbout CFLT Confluent Inc.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.